- Home
- / Sinphar Pharmaceutical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sinphar Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$30.8
2024-10-29
Market Capitalization
NT$5.6 B
2024-10-29
Revenue
NT$3.2 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.4B | 2.4B | 2.4B | 2.9B | 3.0B | 3.2B |
| Cost of goods sold | 1.2B | 1.2B | 1.3B | 1.3B | 1.5B | 1.6B | 1.7B |
| Gross profit | 1.1B | 1.3B | 1.2B | 1.2B | 1.4B | 1.4B | 1.5B |
| Gross profit margin, % | 46.2% | 48.0% | |||||
| Operating expense total | 944.7M | 1.1B | 999.6M | 1.1B | 893.5M | 803.5M | 943.0M |
| Depreciation and amortization | 238.8M | 236.8M | 250.4M | 269.4M | 266.7M | 243.5M | 257.4M |
| EBITDA | 154.6M | 173.7M | 168.1M | 118.5M | 513.2M | 566.0M | 570.4M |
| EBITDA margin, % | 19.1% | 18.1% | |||||
| EBIT | (76.2M) | (65.1M) | (86.3M) | (153.9M) | 246.2M | 325.0M | 313.7M |
| EBIT margin, % | 11.0% | 10.0% | |||||
| Interest income | 5.7M | 3.7M | 3.8M | 3.7M | 5.8M | 12.3M | 16.8M |
| Interest expense | 20.4M | 23.1M | 24.5M | 24.8M | 27.8M | 33.7M | 36.8M |
| Pre tax profit | (87.7M) | (86.7M) | (117.8M) | (184.5M) | 245.0M | 305.7M | 307.1M |
| Income tax expense | 35.3M | 61.2M | 54.8M | 20.4M | 80.9M | (51.1M) | 21.9M |
| Net Income | (123.0M) | (147.9M) | (172.6M) | (205.0M) | 164.2M | 356.8M | 285.2M |